Oncorus Synthetic Day June 2021

Virtual, June 21, 2021

Please join Oncorus for an upcoming investor event focused on its IV-administered Synthetic viral RNA (vNRA) Immunotherapy Platform.

Guest speaker Leena Ghandi, MD, PhD, Director, Center for Cancer Therapeutic Innovation at Dana Farber, will review current clinical practice, anticipated and possible changes to the IO landscape, and the potential for IV-administered viral immunotherapies to address significant unmet needs.  

Oncorus management will discuss the company's pioneering Synthetic vRNA immunotherapy approach, which comprises self-amplifying RNA encoded for oncolytic viruses encapsulated within lipid nanoparticles, or LNPs, and introduce its lead synthetic vRNA product candidates, ONCR-021 and ONCR-788.

This Event Will Occur June 21, 2021 from 1:00 – 2:30 pm EST.

For more information or to RSVP, please contact Josh Rauch at jrauch@soleburytrout.com, or click here

General Agenda

Introduction & OverviewTed Ashburn MD, PhD, President & CEO

Oncorus Synthetic Clinical CandidatesChristophe Quéva PhD, CSO

How IV-Administered Synthetic vRNA Immunotherapies Could Advance Standards of Care in CancerLeena Gandhi MD, PhD, Director, Center for Cancer Therapeutic Innovation, Dana-Farber Cancer Institute

Clinical Development Plans to Rapid Proof of Principle & Proof of ConceptJohn Goldberg MD, SVP Clinical Development

Essential Manufacturing CapabilitiesSteve Harbin COO & Chief of Staff

IND Timelines & Future ProgramsTed Ashburn MD, PhD, President & CEO

Question & Answer Session - All Presenters

RSVP Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Oncorus [ONCR] $248 MM MCap
The com­pany's lead pro­gram ON­CR-177 is a Ph1 oHSV with com­ple­men­tary pay­loads (PD1, CCL4, IL12, FLT3, CT­LA4) to en­cour­age im­mune sti­m­u­la­tion, with read­out guid­ed for 2H21. [more in­for­ma­tion]